BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia
Potential first treatment for achondroplasia in the United States
European Regulatory Review Began on Aug. 13
SAN RAFAEL, Calif., Aug. 20, 2020 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced ... Biopharmaceuticals, FDA BioMarin Pharmaceutical, vosoritide, achondroplasia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Children | Food and Drug Administration (FDA) | Marketing | New Drug Applications | Pharmaceuticals | USA Health